Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

(2016) Claudia Bracaglia et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic-onset juvenile idiopathic arthritis

(2016) Rolando Cimaz   AUTOIMMUNITY REVIEWS

Altered signaling in systemic juvenile idiopathic arthritis monocytes

(2016) Claudia Macaubas et al.   CLINICAL IMMUNOLOGY

Macrophage activation syndrome in the era of biologic therapy

(2016) Alexei A. Grom et al.   Nature Reviews Rheumatology

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat

(2016) Angelo Ravelli et al.   Arthritis & Rheumatology

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

(2015) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies

(2015) Grant S. Schulert et al.   Annual Review of Medicine

Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis

(2015) Masaki Shimizu et al.   CLINICAL IMMUNOLOGY

Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab

(2015) S. Yokota et al.   JOURNAL OF RHEUMATOLOGY

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

(2015) Mikhail M Kostik et al.   Pediatric Rheumatology

HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

(2015) Michael J. Ombrello et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ

(2015) Karen Put et al.   RHEUMATOLOGY

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

(2015) Alexei A. Grom et al.   Arthritis & Rheumatology

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan

(2014) S. Yokota et al.   JOURNAL OF RHEUMATOLOGY

Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis

(2014) Atsuko Iwai et al.   Modern Rheumatology

An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome

(2014) Scott W Canna et al.   NATURE GENETICS

Treatment of juvenile idiopathic arthritis: a revolution in care

(2014) Matthew L Stoll et al.   Pediatric Rheumatology

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab

(2014) Fabrizio De Benedetti et al.   Pediatric Rheumatology

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients

(2014) Francesca Minoia et al.   Arthritis & Rheumatology

Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis

(2014) Sergio Davì et al.   Arthritis & Rheumatology

Long-Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis

(2013) Daniel J. Lovell et al.   ARTHRITIS AND RHEUMATISM

Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

(2013) Sebastiaan J. Vastert et al.   Arthritis & Rheumatology

The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness

(2012) Keith A. Sikora et al.   ARTHRITIS AND RHEUMATISM

P153 Interleukin-6 levels as indicator of macrophage activation syndrome/relaps in systemic juvenile arthritis during anakinra or tocilizumab treatment

(2012) A.M. Kapović et al.   CYTOKINE

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6

(2012) Masaki Shimizu et al.   CYTOKINE

Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment

(2012) A Ravelli et al.   GENES AND IMMUNITY

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

(2012) Elizabeth A Kessler et al.   Pediatric Rheumatology

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients

(2010) P. M. Miettunen et al.   RHEUMATOLOGY

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration

(2009) Claudia Drucker et al.   JOURNAL OF AUTOIMMUNITY

A case of macrophage activation syndrome successfully treated with anakinra

(2008) Alison Kelly et al.   Nature clinical practice. Rheumatology